A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

NCT07699328 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR-Mutant Non-Small Cell Lung Cancer

Interventions

DRUG: VRN110755

Sponsor

Voronoi, Inc